Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification
PARPis significantly improved PFS in elderly ovarian cancer patients with BRCA mutations and HRD, with a toxicity profile similar to that of younger patients. Elderly patients benefited from frequent dose modifications without any negative impact on PFS outcomes.
Authors
- D. Kim
- Myong Cheol Lim (ORCID: https://orcid.org/0000-0001-8964-7158)
- Uisuk Kim (ORCID: https://orcid.org/0000-0002-1279-3701)
- Ji Hyun Kim (ORCID: https://orcid.org/0000-0002-4746-5572)
- Sang‐Yoon Park (ORCID: https://orcid.org/0000-0001-8325-6009)
- Jae Kyung Bae
- W Jin
Institutions
- Western University (CA)
- Yanbian University (CN)
- National Cancer Center (US)
- National Cancer Center (KR)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.3802/jgo.2026.37.e9
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Ministry of Health and Welfare